Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels mediating fundamental physiological activities in the nervous system and have become important targets for drug design. For a long time, the acetylcholine binding protein (AChBP) has been used as a surrogate to study the nAChR structurefunction. Taking advantage of more than 100 AChBP crystal structures in the Protein DataBank (PDB), we explored the relationship between the size, efficiency, and efficacy of nAChR ligands and the C-loop movement. We found that the size of the ligand is correlated with the opening of the C-loop, which can be used in selecting AChBP crystal structures with appropriate C-loop opening to be used for nAChR ligand docking. Ligand size and C-loop opening are reversely correlated with the ligand efficiency rather than the binding affinity. Ligand efficiency could be accurately predicted using simple computational docking, giving a correlation coefficients (R 2 ) up to 0.73. The efficacy of nAChR ligands might be related to ligand size, C-loop opening, and ligand efficiency. Results from this study are useful for engineering the binding affinity and efficacy of nAChR ligands.
INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels involved in fast synaptic transmission and physiological activities in the nervous system.1 nAChRs belong to the cys-loop receptor family, which also includes glycine, serotonin (5-HT3), γ-amino butyric acid type A (GABAA) receptors, and a zinc-activated ion channel.2 There are many different nAChR subtypes with preferential distribution in the nervous system where they mediate different physiological processes. 1 Malfunction of the nAChR is related to neurological disorders such as Parkinson's disease, Alzheimer's disease, schizophrenia, pain, depression, and memory loss. 1, 3, 4 Hence, nAChRs are important targets for drug design. 1, 4 In vertebrates, there are 17 nAChR subunits consisting of α1-α10, β1-β4, γ, δ, and ε. nAChRs are composed of five subunits, with each subunit divided into three domains: an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular domain (ICD) ( Figure 1A ,B).
The ligand binding site is formed by the ECD of two adjacent subunits ( Figure 1C ), consisting of loops A, B, and C of the principal subunit and the β-sheet of the complementary subunit. Recently, the published crystal structure of human α4β2 nAChR (PDB code: 5KXI) 5 showed that the agonist, nicotine, is deeply capped into the ligand binding site with the nicotine positively charged N group oriented to the center of the nAChR aromatic box, forming a cation−π interaction with residue W156. For a long time, the crystal structure of acetylcholine binding protein (AChBP), a homologue of the nAChR ECD, has been used as a template to study nAChR structure and function. 6 Crystal structures of the AChBP in apo, complexed with full agonists, partial agonists, and antagonists, demonstrate that the C-loop of the binding site is very flexible to accommodate the wide spectra of nAChR ligands ( Figure   1D ,E, Table S1 ). 7−17 Agonist binding triggers conformational changes in cys-loop receptors, leading to opening of the channel and, consequently, a flux of ions through the channel pore.
The starting step for nAChR activation by an agonist is capping of the binding site C-loop into closed conformation. 18−21 The conformational state of the C-loop might be related to the functional state of the nAChR. The ligand binding sites of AChBP are highly plastic, allowing binding of various molecules ranging from small neurotransmitters to large peptide neurotoxins, such as α-conotoxins and snake toxins. 7, 17, 22 Analysis of the AChBP bound with various ligands of nAChR indicated that the opening of the C-loop bound with full agonist is comparable to or even more closed than that bound with partial agonist, but the latter is remarkably more closed than that bound with antagonist ( Figure 1D ), in line with the results of Brams et al. 8 It tempts us to assume that a relationship might exists between the conformational states of the C-loop with ligand size, efficiency, and efficacy. In this study, we statistically analyzed 48 crystal structures of AChBP bound with different nAChR ligands (Table S2 , Figure S1 ) 8−17,23−37 to explore the aforementioned relationship between the nAChR ligands and the C-loop.
METHODS

Ligand Size and C-Loop Opening Calculations.
Crystal structures of AChBP bound with nAChR ligands with known binding affinity (PDB   ID: 1UV6, 1UW6, 2WNL, 2BYQ, 3WTN, 3WTL, 2BYS, 3WIP, 3U8J, 3ZDG, 4BQT,   3ZDH, 4AFT, 3U8K, 4B5D, 2ZJV, 3C84, 3U8L, 3C79, 3U8M, 2WNC, 2WN9, 3U8N,   2WNJ, 4AFH, 2XNT, 4ALX, 2PGZ, 2XNU, 2XYS, 2W8F, 2W8G, 2X00, 2XYT, 2BYR,   2WZY, 2C9T, 2BR8, 4BFQ, 4DBM, 4QAA, 4QAB, 4QAC, 2Y54, 2Y56, 2Y57, 2Y58 and 1UX2) were selected and downloaded from the Protein DataBank (PDB, http://www.rcsb.org). The number of heavy atoms for the nAChR ligands was calculated using ChemDraw ( Figure S1 ), and the opening of the C-loop of the AChBP was calculated using Visual Molecular Dynamics (VMD). 38 Ligand Binding Affinity and Ligand Efficiency.
The ligand binding affinity (∆G) was calculated using the equation
where R = 8.314 J·mol−1·K−1, T = 300 K, and Kd is the equilibrium dissociation constant.
Ligand efficiency (∆g) was determined using the equation
where ∆G is the binding free-energy change (or ligand binding affinity) and Nheavy atoms is the number of heavy or non-hydrogen atoms.
39−41
AutoDock Binding Affinity Calculation. The number of LGAs was set using the default values. The produced conformation with minimum binding energy was selected for the analysis.
MOE Binding Affinity Calculation.
Molecular docking was performed using MOE with the AMBER10:EHT force field. Ranking nAChR ligands based on their size in order from low to high showed that the full agonists were mostly at the left (low heavy atom number), the antagonists were at the right (high heavy atom number), and the partial agonists were in the middle ( Figure 2A , Table S2 ).
Notably, the distribution boundary between the partial agonists and antagonists is not clearly defined. Indeed, some of the nAChR ligands are antagonists despite their comparable or smaller size than that of the partial agonists. Similarly, using the distance of the C-loop opening as the ranking parameter of the ligands (from smallest to largest shift), the agonists had the least and modest impact on the C-loop movement, respectively. The antagonists, however, resulted in the largest shift of the C-loop opening ( Figure 2B , Table S2 ). However, unlike the ligand size distribution profile, the boundary between the agonists and antagonists is more clearly defined. Thus, C-loop opening measurement is a more reliable indicator to differentiate the agonists from the antagonists of the nAChR.
The correlation between the C-loop shift and nAChR agonist efficacy though, is unclear ( Figure 2B ). Indeed, there remains controversy over the correlation between the opening of the C-loop and agonist efficacy of the nAChR. 8, 24, 37 It is challenging to use the limited number of AChBP crystal structures to thoroughly understand the structure−function relationships of nAChR agonists. The AChBP crystal structure is homologus to the ECD of nAChR, and therefore, the conformational state of the C-loop on AChBP might not be exactly the same to that of the nAChR as trivial differences exist. 47, 48 In addition, nAChR agonists can behave differently at different nAChR subtypes. For instance, nicotine activates other subtypes of nAChR while antagonizing the α9α10 nAChR subtype. 49, 50 In addition, choline is a known α7 nAChR subtype-selective agonist but acts as a partial agonist for some other nAChR subtypes. 
where x is the number of heavy atoms.
To date, over 100 crystal structures of AChBP bound with different nAChRs ligands are available in the PDB, providing sufficient models of the C-loop movement to understand the ligand nAChR structure−activity relationship. 16, 52 Correct selection of the crystal structures is essential for accurate docking models of nAChR ligands. Here, we proposed the use of eq 3 in selecting suitable ligand-bound AChBP crystal structures for generation of docking models. To evaluate the accuracy of eq 3 in predicting the opening of the C-loop of AChBP, we randomly chose four nAChR ligands (Table 1) were used for docking ( Figure S4 ). Thus, the conformational state of the C-loop and selection of the correct crystal structures for nAChR molecular docking or as a homology modeling template should be considered in future modeling studies of the nAChR ligands.
Ranking of the ligands based on their binding affinity resulted in irregular distribution ( Figure 5A , Table S2 ). In contrast, using the binding efficiency of the agonists and antagonists as the ranking parameter, most of the full agonists had the highest binding efficiency followed by the partial agonists and the antagonists with the lowest efficiency ( Figure 5B , Table S2 ). Thus, the binding efficiency of the ligands rather than their binding affinities could be used to differentiate the agonists from the antagonists of the nAChR.
Our analysis also indicated that no correlation was found between ligand size and binding affinity (R 2 = 0.05) ( Figure 5C ), whereas a strong linear correlation was identified (R
between the logarithm of the number of the heavy atoms (or ligand size) and ligand efficiency ( Figure 5D ). Indeed, comparison of protein−ligand binding affinities for over 8000
ligands with 28 protein targets shows that the ligand efficiency rather than average ligand binding affinities is correlated with molecular size. 55 Large ligands usually form more contacts with the receptor than smaller size ligands, whereas the binding affinities of the former do not overwhelm that of the latter ( Figure 5A , Table S2 ). Thus, it is not rational to improve the binding affinity of the nAChR ligands merely by increasing the ligand size.
Instead, optimization of their structure and functional groups might be a more feasible choice. Figure 2B ). 8, 24 Ligand efficiency, simply defined as ligand binding in terms of free energy per heavy atom, 39, 40 could be useful in deciding the potential further optimization of particular "hits"
and chemical scaffolds. The efficacy of a ligand, on the other hand, is generally determined by the ligand's ability to promote a quantifiable biological response upon binding. 56 We found that there might be some correlation between ligand efficiency and ligand efficacy for nAChR ligands ( Figure 5B ). In comparison to ligand size, ligand efficiency might be a more reliable indicator to differentiate the agonists from the antagonists of the nAChR as ligand efficiency takes into account the size and binding affinity of the ligand (Equation 2). Indeed, a small size ligand with very poor binding affinity cannot function as a full agonist, until it binds to the nAChR and caps the C-loop into the closed conformation.
Interestingly, we found that ligand efficiencies could be simply predicted using computational docking. As shown in Figure 6A ,B, the predicted ligand efficiencies using MOE and ADT are well correlated with the experimentally determined ligand efficiencies (R 2 = 0.57 and 0.73, respectively) ( Figure S5 ). We also evaluated the performance of MMPBSA at predicting ligand efficiency, and we found that its performance is comparable to ADT but a little inferior to MOE ( Figure 6C ,D and Figure S6 ). Overall, the ligand efficiency could be well predicted using molecular docking, an extremely fast and economical binding affinity calculation method. determined using experimental approaches. In total, 61 compounds were docked into AChBP using ADT, while 59 nonpeptide compounds were selected for docking using MOE. MOE is poor at binding mode determination of peptides, and they were excluded in the docking set. 
CONCLUSIONS
